Gynecomastia Surgery in Barcelona Spain

Gynecomastia Surgery
Male Breast Reduction

Based upon Wikipedia, the free encyclopedia

Gynecomastia, or gynaecomastia, is the development of abnormally large mammary glands in males resulting in breast enlargement, which can sometimes cause secretion of milk.
The term comes from the Greek gyne meaning "woman" and mastos meaning "breast".

The condition can occur physiologically in neonates (young babies), in adolescents, and in the elderly. In adolescent boys the condition is often a source of distress, but for the large majority of boys whose pubertal gynecomastia is not due to obesity, the breast development shrinks or disappears within a couple of years.

The causes of common gynecomastia remain uncertain, although it has generally been attributed to an imbalance of sex hormones or the tissue responsiveness to them; a root cause is rarely determined for individual cases.

Gynecomastia occurs in approximately 50% of all men in different forms, ranging from excess breast or fat tissue to the development of female glands.

In some cases, changes in lifestyle or diet can reverse gynecomastia, and in 90% of adolescents the condition disappears within a month or two.  For all others surgery is the only option for correction.

Causes of Gynecomastia
It can develop in adolescents as early as age twelve as a result of hormonal changes. It can also be caused by drug, diet, and lifestyle induced hormonal shifts.

Men taking anabolic steroids often suffer from gynecomastia as testosterone levels in the body rise dramatically, causing the body to respond by producing enzymes that turn excess testosterone into estrogen.
Increased age and weight can also contribute to the development of excess breast and fat tissue.

Physiologic gynecomastia occurs in neonates (young babies), at or before puberty and with aging. Many cases of gynecomastia are idiopathic, meaning they have no clear cause.
Potential pathologic causes of gynecomastia are:
• Medications including hormones;
• Increased serum estrogen;
• Decreased testosterone production;
• Androgen receptor defects;
• Chronic kidney disease;
• Chronic liver disease;
• HIV; and
• Other chronic illness.

Gynecomastia as a result of spinal cord injury and re-feeding after starvation has been reported. In 25% of cases, the cause of the gynecomastia is not known.

Medications cause 10-20% of cases of gynecomastia in post-adolescent adults. These include cimetidine, omeprazole, spironolactone, Imatinib Mesylate, finasteride and certain antipsychotics. Some act directly on the breast tissue, while others lead to increased secretion of prolactin from the pituitary by blocking the actions of dopamine (prolactin-inhibiting factor/PIF) on the lactotrope cell groups in the anterior pituitary. Androstenedione, used as a performance enhancing food supplement, can lead to breast enlargement by excess estrogen activity. Medications used in the treatment of prostate cancer, such as antiandrogens and GnRH analogs can also cause gynecomastia. Marijuana use is also thought by some to be a possible cause; however, published data is contradictory.

Increased estrogen levels can also occur in certain testicular tumors, and in hyperthyroidism. Certain adrenal tumors cause elevated levels of androstenedione which is converted by the enzyme aromatase into estrone, a form of estrogen. Other tumors that secrete hCG can increase estrogen. A decrease in estrogen clearance can occur in liver disease, and this may be the mechanism of gynecomastia in liver cirrhosis. Obesity tends to increase estrogen levels.

Decreased testosterone production can occur in congenital or acquired testicular failure, for example in genetic disorders such as Klinefelter Syndrome. Diseases of the hypothalamus or pituitary can also lead to low testosterone. Abuse of anabolic androgenic steroids (AAS) has a similar effect. Mutations to androgen receptors, such as those found in Kennedy disease can also cause gynecomastia.

Although stopping these medications can lead to regression of the gynecomastia, surgery is sometimes necessary to eliminate the condition.

Repeated topical application of products containing lavender and tea tree oils among other unidentified ingredients to three prepubescent males coincided with gynecomastia; it has been theorised that this could be due to their estrogenic and antiandrogenic activity. However, other circumstances around the study are not clear, and the sample size was insignificant so serious scientific conclusions cannot be drawn.


Diagnosis
The condition usually can be diagnosed by examination by a physician. Occasionally, imaging by X-rays or ultrasound is needed to confirm the diagnosis. Blood tests are required to see if there is any underlying disease causing the gynecomastia.


Prognosis
Gynecomastia is not physically harmful, but in some cases can be an indicator of other more dangerous underlying conditions. Growing glandular tissue, typically from some form of hormonal stimulation, is often tender or painful. Furthermore, it can frequently present social and psychological difficulties for the sufferer. Weight loss can alter the condition in cases where it is triggered by obesity, but losing weight will not reduce the glandular component and patients cannot target areas for weight loss. Massive weight loss can result in sagging tissues about the chest, chest ptosis, or drooping chest.

Treatment: non-surgical
Treating the underlying cause of the gynecomastia may lead to improvement in the condition.

Patients should talk with their doctor about revising any medications that are found to be causing gynecomastia; often, an alternative medication can be found that avoids gynecomastia side-effects, while still treating the primary condition for which the original medication was found not to be suitable due to causing gynecomastia side-effects (e.g., in place of taking spironolactone the alternative eplerenone can be used).

Selective estrogen receptor modulator medications, such as tamoxifen and clomiphene, or androgens or aromatase inhibitors such as Letrozole are medical treatment options, although they are not universally approved for the treatment of gynecomastia. Endocrinological attention may help during the first 2-3 years.

Treatment: surgical
After the above non-surgical options, however, the breast tissue tends to remain and harden, leaving surgery the only treatment option.
The surgical methods include:
• Liposuction;
• Gland excision;
• Skin sculpture;
• Reduction mammoplasty; or
• Combination of these surgical techniques.

 

The surgical procedure
Usually performed in a doctor's office or surgical suite as an outpatient procedure, gynecomastia surgery can be done with the use of a local or general anesthetic.

Once the patient is properly anesthetized, the surgeon makes a small incision just below the areola.  Excess breast tissue is surgically excised from the area and fat is removed with the use of liposuction.  The incision is then closed and the patient is detained until the effects of the anesthesia wear off.


Recovery
After surgery you will be fitted with a compression garment or ace bandages to support the breasts while they heal.  The recovery process is usually not a short one.  Patients should take their time when thinking about returning to normal activity, and are usually told to ease back into their daily routine gradually.  In many instances patients will wait between one and three weeks before returning to work.


Complications
Most instances of complications stem from surgeon error and patients trying to do too much after surgery.  The most serious complications include:
• Hematoma (collection of blood);
• Asymmetry;
• Infection;
• Change in position or shape of the nipple; and
• Wound separation.
More common complications include:
• Numbness;
• Swelling;
• Bruising, and
• Scarring.


Who can be a candidate?
Men who have developed larger, female-like breasts and have not been able to alter this problem with diet and lifestyle changes can be candidates for surgery.


Average costs
Including costs of anesthesia and other necessary equipment and medications costs can average $2,000 to $6,000 or more, depending on the clinic and the geographic location.

More Barcelona info...


  • Barcelona Districts Parc Diagonal Mar
    Barcelona has many quarters, but the most important and interesting for visitors are:
    -


  • Barcelona By rail
    Several trains per day (including overnight hotel trains) from other parts of Europe (via France) are regular & reliable.

    The long-delayed AVE high-speed train line is finally expected to reach Sant Joan Desp? station, on the outskirts of Barcelona, by the end of 2007. Travel time from Madrid is expected to be around 3 hours, compared to 5 hours by normal train.
    -

Plastic Surgery News...

  • Meta-analysis of data from controlled trials has found that in postmenopausal women with breast cancer, aromatase-inhibitor treatment is associated with a statistically significant but small increase in risk of cardiovascular events. The authors note that the aromatase inhibitors are more effective than tamoxifen in the treatment of breast cancer; however reports suggest that they may be associated with a higher cardiovascular risk. This analysis aimed to clarify the risk to benefit balance for these drugs. The authors carried out a comprehensive search, mostly using specialist sources, for long-term (five year) randomised controlled trials of aromatase inhibitors against tamoxifen after surgery in women with breast cancer where data on cardiovascular adverse events were reported. From this data, they derived the event risk-ratios and absolute event rates with the two drug groups. Primary outcome was grade 3 and 4 cardiovascular adverse events. The initial search located ten potentially relevant trials of which 7 (n=19,818) were eligible for the analysis. All had been published in full, and three had subsequent updates. On the primary outcome, there was an increased risk of 0.52% in the aromatase inhibitor arm compared to the tamoxifen arm; a risk ratio of 1.31 (95% CI, 1.07 to 1.60; P =0.007). Thromboembolic events were a secondary outcome, and these were less likely than in the tamoxifen arm (RR, 0.53; 95% CI, 0.42 to 0.65; P <0.0001). The authors conclude that treatment with aromatase inhibitors is associated with a small increase in risk of cardiovascular adverse events - while this is statistically significant, the number needed to harm is around 160 to 180. It may be balanced by a reduced risk of thromboembolic events.

  • The authors of this article discuss whether monitoring initial response to treatment is always helpful in the clinical management of patients. They have developed a framework for deciding whether surrogate outcomes should be used to monitor initial response to treatment in chronic disease. To develop the framework, the authors looked at two scenarios: - Should change in blood pressure be monitored after addition of a diuretic to an angiotensin II receptor blocker in adults with essential hypertension? - Should change in cholesterol be monitored after giving patients with ischaemic heart disease a statin? The following topics are covered in the article: • Rationale and pitfalls of monitoring initial response • Estimating variability in treatment effects between individuals from placebo controlled randomised trials • Blood pressure and lipid lowering • A framework for choosing whether to monitor initial response to a new drug • What to do next The main summary points (taken directly from the article) are provided below: o Clinicians routinely monitor individual patients after they start a new treatment; sometimes this may be unnecessary and even potentially harmful o Monitoring is unlikely to be of value when there is no evidence of variation in the response to treatment or when there is a high probability that therapeutic targets will be met o Data from placebo controlled randomised trials can be used to decide on the need for monitoring initial response in different clinical scenarios o Updating the CONSORT statement to include the detailed reporting of outcome variability will allow clinicians to make informed decisions on the need to monitor initial response to treatment

Ask A Local Surgeon
From Barcelona

»Have a Local Immersivemedical member contact you«

Gynecomastia Surgery Surgeons in Barcelona

Your Clinic NameYour Clinic Name
Join us and get your clinic listed here.
also join our referral system and get referring customers in your area.

..



»Add Your clinic Here«»Recommend a Clinic«

Plastic Surgery Articles


»Add Your Article«


Buttock Implants in Barcelona, Eyelid Surgery in Barcelona, Body Contouring in Barcelona, Botox® Cosmetic in Barcelona, Breast Augmentation in Barcelona, Breast Reduction in Barcelona, Buttock Augmentation in Barcelona, Chemical Peel in Barcelona, Chin Augmentation in Barcelona, Correction Of Breast Asymmetry in Barcelona, Ear Surgery in Barcelona, Facelift in Barcelona, Fat Grafting in Barcelona, Gastric Bypass in Barcelona, Hair Replacement in Barcelona, Jaw Surgery in Barcelona, Lip Augmentation in Barcelona, Liposuction in Barcelona, Male Breast Reduction in Barcelona, Neck Lift in Barcelona, Penis Enlargement in Barcelona, Spider Vein Treatment in Barcelona, Breast Reconstruction in Barcelona, Nose Reshaping in Barcelona, Dermabrasion in Barcelona, Vaginal Surgery in Barcelona, Medical Tourism in Barcelona, Plastic Surgeon in Barcelona, Arm Lift in Barcelona, Tummy Tuck in Barcelona, Hyperhydrosis in Barcelona, Nose Surgery in Barcelona, Hair Transplant in Barcelona, Cellulite Treatment in Barcelona, Hair Removal in Barcelona, Tattoo Removal in Barcelona, Cheek Augmentation in Barcelona, Inverted Nipple Repair in Barcelona, Skin Resurfacing in Barcelona, Body Procedures in Barcelona, Permanent Cosmetics in Barcelona, Face Procedures in Barcelona, Skin Surgery1 in Barcelona, Calf Augmentation in Barcelona, Birthmark Removal in Barcelona